Comparison of scar treatment response and recovery of skin reaction after ablative fractional laser according to topical application of stem cell in atrophic scar patients

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0003718

Enrollment

Registered

2019-04-04

Start date

2018-01-16

Completion date

Unknown

Last updated

2019-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug, Biological/Vaccine, Stem Cell : 1. Types of laser instruments and drugs used 1) Ablative fractional laser 2) SCM2® - Component: Human body stem cells culture fluid 100&#37

- Packing unit: 2ml x 10 vials / pack 3) TheraStem-Derma® - Component: Human body fat derived stem cell culture 80&#37

, hyaluronic acid - Packing unit: 1ml X 6 amples / pack 4) Control - Use normal saline when applying immediately after the procedure - When applying for one week after the procedure, use TheraStem-Der

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Subjects who visited our dermatology clinic and were diagnosed with atrophic scar on those face - Adults from 19 to 65 years of age - Subjects who voluntarily signed a written consent with hearing the purpose and contents of the examination before the examination - Subjects who can be followed up during the test

Exclusion criteria

Exclusion criteria: - Subjects who disagree or do not fill out a consent form - Subjects who are currently confirmed as pregnant (do not conduct pregnancy tests separately). - Subjects who are currently lactating - Subjects who have infectious skin disease on face - Subjects who take retinoid drugs (Isotretinoin, acitretin, alitretinoin, etc.) within 1 month of the test - Subjects who have serious systemic or chronic diseases (hypertension, diabetes, etc.) - In case of difficulty in measurement due to other skin lesions on the test site - Subjects who are exposed to cosmetics, medicines or daily light exposure or are allergic to them - Subjects who are applying other drugs to the face - Subjects who are judged that it is difficult to be included to the research by the judgment of the research examiner

Design outcomes

Primary

Measure	Time frame
Difference of erythema index between both sides of face;Improvement of scar;Adverse reaction after use of test agent	—

Secondary

Measure	Time frame
Subject's satisfaction with laser treatment measured with a VAS scale	—

Countries

Korea, Republic of

Contacts

Public ContactJong Hee Lee

Samsung Medical Center

bell711@hanmail.net+82-2-3410-3549

Outcome results